Target Name: IL19
NCBI ID: G29949
Other Name(s): IL-19 | IL-10C | Melanoma differentiation associated protein-like protein | Interleukin-19 | ZMDA1 | Melanoma differentiation-associated protein-like protein | melanoma differentiation associated protein-like protein | Interleukin-19 precursor | IL19 variant 1 | interleukin 19 | MDA1 | IL19_HUMAN | Interleukin 19, transcript variant 1 | NG.1

IL-19: A Potential Drug Target and Biomarker

IL-19 (Interleukin-19) is a cytokine that plays a crucial role in the immune system and has been implicated in a number of diseases, including autoimmune disorders, cancer, and obesity. Despite its importance, little is known about IL-19 and its potential as a drug target or biomarker. In this article, we will explore the biology and function of IL-19, as well as its potential as a drug target and biomarker.

The biology of IL-19

IL-19 is a cytokine that is expressed in a variety of tissues, including the immune system, skin, and muscle. It is a member of the IL-1 family of cytokines, which include IL-1, IL-2, IL-3, and IL-4. IL-19 is characterized by its ability to induce cell proliferation and differentiate, as well as its ability to stimulate the production of pro-inflammatory cytokines.

One of the key functions of IL-19 is its ability to regulate the immune system. IL-19 has been shown to play a role in the regulation of T cell development and function, as well as the regulation of inflammation. It has also been shown to have anti-inflammatory effects and to be involved in the regulation of pain perception.

In addition to its role in the immune system, IL-19 is also involved in the regulation of cell survival and metabolism. It has been shown to play a role in the regulation of cell proliferation, differentiation, and apoptosis, as well as in the regulation of metabolism.

The potential as a drug target

The potential of IL-19 as a drug target is due to its ability to induce cell proliferation and differentiate, as well as its ability to stimulate the production of pro-inflammatory cytokines. It is also due to its involvement in the regulation of the immune system, cell survival and metabolism.

One potential mechanism by which IL-19 could be targeted as a drug is its ability to stimulate the production of pro-inflammatory cytokines. Pro-inflammatory cytokines, such as TNF-alpha, IL-1, and IL-6, have been shown to play a role in a variety of diseases, including cancer, autoimmune disorders, and obesity. By inhibiting the production of these cytokines, IL-19 may have the potential to be used as a therapeutic agent for a variety of diseases.

Another potential mechanism by which IL-19 could be targeted as a drug is its ability to induce cell proliferation and differentiation. Prolonged exposure to IL-19 has been shown to lead to the development of cancer, and it is thought that this is due to the ability of IL-19 to stimulate the production of progenitor cells. By inhibiting the production of progenitor cells, IL-19 may have the potential to be used as a therapeutic agent for cancer.

The potential as a biomarker

The potential of IL-19 as a biomarker is due to its ability to be easily measured and its ability to be affected by a variety of factors, such as diet and exercise.IL-19 is a cytokine that is expressed in a variety of tissues, including the immune system, skin, and muscle. It is a member of the IL-1 family of cytokines, which include IL-1, IL-2, IL-3, and IL-4. IL-19 is characterized by its ability to induce cell proliferation and differentiate, as well as its ability to stimulate the production of pro-inflammatory cytokines.

One of the key functions of IL-19 is its ability to regulate the immune system. IL-19 has been shown to play

Protein Name: Interleukin 19

Functions: Cytokine that functions as an anti-inflammatory and proangiogenic factor (PubMed:34932373). Polarizes adaptive immunity to an anti-inflammatory phenotype through induction of T-helper 2 responses by both down-regulation of IFN-gamma and up-regulation of IL4 and IL13 (PubMed:16365913). Produced by osteocytes, stimulates granulopoiesis and neutrophil formation (By similarity). Exerts its biological effect through a receptor complex consisting of a heterodimer of IL20RA and IL20RB (PubMed:12351624). In turn, activates the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway, and importantly, STAT3 (PubMed:11564763)

More Common Targets

IL1A | IL1B | IL1F10 | IL1R1 | IL1R2 | IL1RAP | IL1RAPL1 | IL1RAPL2 | IL1RL1 | IL1RL2 | IL1RN | IL2 | IL20 | IL20RA | IL20RB | IL21 | IL21-AS1 | IL21R | IL21R-AS1 | IL22 | IL22RA1 | IL22RA2 | IL23A | IL23R | IL24 | IL25 | IL26 | IL27 | IL27RA | IL2RA | IL2RB | IL2RG | IL3 | IL31 | IL31RA | IL32 | IL33 | IL34 | IL36A | IL36B | IL36G | IL36RN | IL37 | IL3RA | IL4 | IL4I1 | IL4R | IL5 | IL5RA | IL6 | IL6-AS1 | IL6R | IL6R-AS1 | IL6ST | IL6ST-DT | IL6STP1 | IL7 | IL7R | IL9 | IL9R | IL9RP3 | IL9RP4 | ILDR1 | ILDR2 | ILF2 | ILF3 | ILF3-DT | ILK | ILKAP | ILRUN | ILVBL | Imidazoline I2 receptor (I2) | Imidazoline I3 receptor (I3) | Imidazoline receptor | IMMP1L | IMMP2L | IMMT | IMMTP1 | Immunoglobulin A | Immunoglobulin E (IgE) | Immunoglobulin G | Immunoglobulin M | Immunoglobulin-Like Domain Containing Receptor | Immunoproteasome | IMP3 | IMP4 | IMPA1 | IMPA1P1 | IMPA2 | IMPACT | IMPDH1 | IMPDH1P10 | IMPDH1P6 | IMPDH2 | IMPG1 | IMPG2 | INA | INAFM1 | INAFM2 | INAVA